MetLife Investment Management LLC Sells 1,185 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

MetLife Investment Management LLC cut its position in Henry Schein, Inc. (NASDAQ:HSIC) by 3.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,961 shares of the company’s stock after selling 1,185 shares during the quarter. MetLife Investment Management LLC’s holdings in Henry Schein were worth $2,403,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in HSIC. ING Groep NV bought a new position in Henry Schein in the third quarter worth about $63,226,000. Thompson Siegel & Walmsley LLC acquired a new position in shares of Henry Schein during the second quarter valued at about $46,683,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Henry Schein during the third quarter valued at about $43,740,000. Bank of Montreal Can increased its holdings in shares of Henry Schein by 365.6% during the third quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock valued at $52,095,000 after acquiring an additional 558,689 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Henry Schein by 1,622.3% during the third quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock valued at $33,449,000 after acquiring an additional 432,187 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Insider Activity

In other news, SVP Lorelei Mcglynn sold 21,035 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. This trade represents a 22.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the transaction, the chief operating officer now directly owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Henry Schein Trading Down 1.0 %

Henry Schein stock opened at $74.49 on Thursday. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a 12 month low of $63.67 and a 12 month high of $82.63. The stock’s 50 day simple moving average is $71.76 and its two-hundred day simple moving average is $69.92. The firm has a market cap of $9.29 billion, a PE ratio of 30.65, a P/E/G ratio of 2.20 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. During the same quarter last year, the firm posted $1.32 EPS. The business’s revenue was up .4% on a year-over-year basis. Analysts anticipate that Henry Schein, Inc. will post 4.78 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on HSIC. Barrington Research restated an “outperform” rating and set a $82.00 price objective on shares of Henry Schein in a report on Wednesday, November 6th. Mizuho initiated coverage on shares of Henry Schein in a report on Wednesday. They set a “neutral” rating and a $75.00 price objective on the stock. StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Robert W. Baird dropped their target price on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, Evercore ISI upped their target price on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. Seven research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Henry Schein presently has an average rating of “Moderate Buy” and a consensus price target of $78.89.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.